David Dow
About David Dow
David Dow serves as the Senior Director of Allogeneic Research at Adaptimmune, where he has worked since 2021. He possesses extensive expertise in CRISPR genome editing and drug discovery processes, with a notable background in translational research and cancer immunotherapy.
Work at Adaptimmune
David Dow has been serving as the Senior Director of Allogeneic Research at Adaptimmune since 2021. In this role, he focuses on advancing research initiatives related to allogeneic therapies, contributing to the company's mission of developing innovative cell therapies for cancer treatment.
Previous Experience at GlaxoSmithKline
Prior to his current position, David Dow held multiple roles at GlaxoSmithKline from 1999 to 2021. He began as a Senior Research Scientist in Pharmacogenetics, later becoming a Group Leader in Target and Pathway Validation, and subsequently served as Program Leader for Cancer Immunotherapy. His extensive tenure at GlaxoSmithKline spanned over 15 years, during which he led various projects in molecular and cellular technologies.
Education and Expertise
David Dow holds a Ph.D. in Genomic Medicine from the University of East Anglia and has completed advanced studies in Genomic Pathology, achieving MRCPath and FRCPath certifications from the Royal College of Pathologists in 2008. He also studied at the Said Business School at the University of Oxford. His expertise includes CRISPR genome editing, drug discovery processes, and advanced genomic technologies such as Next Generation Sequencing (NGS) and transcriptomics.
Involvement in Academia
Since 2016, David Dow has been a Visiting/Guest Lecturer at the University of Cambridge. In this capacity, he shares his knowledge and experience in genomic medicine and research methodologies with students and fellow researchers, contributing to the academic community.
Research Focus and Contributions
David Dow's research primarily focuses on translational studies in cell and gene therapy, including involvement in projects like Strimvelis. He specializes in the drug discovery process, from target validation to the initiation of human trials, and has experience with organoid cell systems in research.